Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

Journal of Pathology

Volumn 227, Issue 1, 2012, Pages 42-52

  Hernandez, Lucia ^a,b   Wilkerson, Paul M ^a   Lambros, Maryou B ^a   Campion Flora, Adriana ^a   Rodrigues, Daniel Nava ^a   Gauthier, Arnaud ^a,c   Cabral, Cecilia ^a   Pawar, Vidyav ^g   Mackay, Alan ^a   A'Hern, Roger ^a   Marchiò, Caterina ^d   Palacios, Jose ^e   Natrajan, Rachael ^a   Weigelt, Britta ^a,f   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c INSTITUT CURIE   (France)

^d UNIVERSITY OF TURIN   (Italy)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g NONE

Author keywords

DCIS; Evolution; Fluorescence in situ hybridization; Heterogeneity; Microarray based comparative genomic hybridization; Progression; Sequenom MassARRAY

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CARCINOMA IN SITU; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLONAL EVOLUTION; CLONE CELLS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84859637667     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3990     Document Type: Article

References (52)

1. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication and prediction. Lancet 2011; 378: 1812-1823.
2. Weigelt B, Pusztai L, Ashworth A, et al. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2011; 9: 58-64.
3. Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220: 562-573.
4. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-94.
5. Navin N, Krasnitz A, Rodgers L, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010; 20: 68-80.
6. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
7. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
8. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103: 1139-1143.
9. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-38.
10. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441. (Pubitemid 38419997)
11. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term followup. Cancer 2005; 103: 2481-2484. (Pubitemid 40800525)
12. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010; 57: 171-192.
13. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974-5979. (Pubitemid 36576916)
14. Robanus-Maandag EC, Bosch CA, Kristel PM, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 2003; 201: 75-82. (Pubitemid 37121205)
15. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 1956-1965. (Pubitemid 351551104)
16. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 2005; 10: 231-247.
17. Schnitt SJ. The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res 2009; 11: 101.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
19. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394-406. (Pubitemid 351609443)
20. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011; 13: 227.
21. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metast 2007; 24: 647-656. (Pubitemid 350159738)
22. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
23. Barker HE, Chang J, Cox TR, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011; 71: 1561-1572.
24. Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu over-expression/ amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002; 15: 1318-1325. (Pubitemid 35463000)
25. Park K, Han S, Kim HJ, et al. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006; 48: 702-707.
26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
27. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
28. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44. (Pubitemid 352009225)
29. Abdel-Fatah TM, Powe DG, Agboola J, et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2010; 220: 419-434.
30. Duprez R, Wilkerson PM, Lacroix-Triki M, et al. Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol 2012; 226: 427-41.
31. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012; 226: 84-96.
32. Marchio C, Iravani M, Natrajan R, et al. Mixed micropapillary- ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009; 218: 301-315.
33. Coe BP, Ylstra B, Carvalho B, et al. Resolving the resolution of array CGH. Genomics 2007; 89: 647-653. (Pubitemid 46589944)
34. Tan DS, Lambros MB, Natrajan R, et al. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007; 87: 737-754. (Pubitemid 47077258)
35. Gunnarsson R, Staaf J, Jansson M, et al. Screening for copynumber alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47: 697-711. (Pubitemid 351847582)
36. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
37. Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282-298.
38. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007; 38: 1105-1122. (Pubitemid 47058171)
39. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006; 86: 398-408.
40. Moelans CB, de Wegers RA, Monsuurs HN, et al. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr) 2011; 34: 475-482.
41. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 1999; 187: 396-402. (Pubitemid 29118269)
42. Di Cosimo S, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: a 'good' activating mutation? Clin Cancer Res 2009; 15: 5017-5019.
43. Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010; 70: 5674-5678.
44. Qi L, Bart J, Tan LP, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 2009; 9: 163.
45. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899-905. (Pubitemid 41077119)
46. Kalinsky K, Heguy A, Bhanot UK, et al. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 2011; 129: 635-643.
47. Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2010; 120: 409-418.
48. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008; 14: 370-378. (Pubitemid 351226103)
49. Park SY, Gonen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010; 120: 636-644.
50. Hwang ES, DeVries S, Chew KL, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004; 10: 5160-5167. (Pubitemid 39099791)
51. Yao J, Weremowicz S, Feng B, et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 2006; 66: 4065-4078.
52. Miller FR, Santner SJ, Tait L, et al. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000; 92: 1185-1186.